Inhibition of late sodium current to reduce electrical and mechanical dysfunction of ischaemic myocardium

Area of Science:

• Cardiology
• Pharmacology
• Electrophysiology

Background:

• The late sodium current (late I(Na)) plays a pathological role in the heart, particularly in ischaemic heart disease.
• Increased late I(Na) contributes to myocardial Ca(2+) overload, electrical instability, and mechanical dysfunction.

Discussion:

• Inhibiting late I(Na) is a promising therapeutic target for managing ischaemic heart disease.
• Ranolazine, a known inhibitor of late I(Na), has demonstrated safety and efficacy in reducing recurrent ischaemia and arrhythmias in clinical trials.
• The development of new late I(Na) inhibitors presents therapeutic opportunities and challenges.

Key Insights:

• Clinical outcome trials, such as MERLIN, indicate that ranolazine is safe and reduces ischaemic and arrhythmic events.
• Evidence suggests that reducing cardiac late I(Na) mitigates ischaemia, Ca(2+) overload, and cardiac dysfunction.
• The findings support the therapeutic benefit and safety of targeting late I(Na) in cardiac conditions.

Outlook:

• Further research into the development and application of late I(Na) inhibitors is warranted.
• Exploring the full therapeutic potential of late I(Na) inhibition in various cardiac pathologies is crucial.
• Addressing the challenges in developing novel late I(Na) inhibitors could lead to improved patient outcomes.